Sphenopalatine Ganglion Blocks for the Treatment of Trigeminal Neuralgia Flares

Medicare Part D Utilization, Spending, and Formulary Coverage of Brand-name Disease Modifying Therapies with Generics Available for Multiple Sclerosis

Reduced Cerebrospinal Fluid Biomarkers (Neurofilament Light Chain, B Cells, T Cells) and Improved Clinical/Imaging Assessments of Disease Activity Are Sustained After 5 Years of Ocrelizumab Treatment: Long-term Extension Results from OBOE